Pancreatic Cancer Research

ResearcherMedical College of WisconsinActive in the last 2 years

Syed Arif Ahmad

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0007-3489-411X; OpenAlex author ID A5103879166. Sources: OpenAlex.

Their work

Papers
13 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
79
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: none · 2022: none · 2023: 2 papers · 2024: 2 papers · 2025: none · 2026: 2 papers

Papers 13

  1. Updates on Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma. Last author DOI 10.1016/j.hoc.2025.07.010↗
  2. CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-1835↗
  3. Lymph node metrics following neoadjuvant therapy to refine patient selection for adjuvant chemotherapy in resected pancreatic cancer: A multi-institutional ana… Co-author DOI 10.1002/jso.27798↗
  4. Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2024.01.013↗
  5. Acid sphingomyelinase expression is associated with survival in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00109-023-02331-6↗
  6. Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset Pancreatic Cancer. Co-author DOI 10.1200/po.23.00152↗
  7. Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectabl… Co-author DOI 10.1097/sla.0000000000004155↗
  8. Murine- and Human-Derived Autologous Organoid/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers12123816↗
  9. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002957↗
  10. Clinical Considerations for Pancreatic Cancer. First author DOI 10.1053/j.ro.2016.02.002↗
  11. Levels of Alternatively Spliced Tissue Factor in the Plasma of Patients with Pancreatic Cancer May Help Predict Aggressive Tumor Phenotype. Co-author DOI 10.1245/s10434-015-4592-2↗
  12. Impact of diabetes mellitus on the outcome of pancreatic cancer. Co-author DOI 10.1371/journal.pone.0098511↗
  13. Borderline resectable pancreatic cancer: pushing the technical limits of surgery. First author PMID 23359915↗

Closest collaborators

The 25 strongest of 79 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gregory C. Wilson · 4 shared papers, 2023–2026 · strength 0.98
  2. Sameer H. Patel · 2 shared papers, 2023–2026 · strength 0.68
  3. Muhammad Shaalan Beg · 3 shared papers, 2014–2024 · strength 0.32
  4. David A. Kooby · 2 shared papers, 2023–2024 · strength 0.30
  5. Ifeanyichukwu Chinedu Ogobuiro · 2 shared papers, 2023–2024 · strength 0.30
  6. Daniel Erik Abbott · 2 shared papers, 2023–2024 · strength 0.30
  7. Nipun B. Merchant · 2 shared papers, 2023–2024 · strength 0.30
  8. Shishir Kumar Maithel · 2 shared papers, 2023–2024 · strength 0.30
  9. Davendra P. S. Sohal · 2 shared papers, 2020–2024 · strength 0.27
  10. Andrew M. Lowy · 2 shared papers, 2020–2024 · strength 0.27
  11. Andrea Wang‐Gillam · 2 shared papers, 2020–2024 · strength 0.27
  12. Philip A. Philip · 2 shared papers, 2020–2024 · strength 0.27
  13. Elena Gabriela Chiorean · 2 shared papers, 2020–2024 · strength 0.27
  14. Rachna T. Shroff · 2 shared papers, 2020–2023 · strength 0.23
  15. Szu-Aun Lim · 1 shared paper, 2026 · strength 0.21
  16. A. Cole Edwards · 1 shared paper, 2026 · strength 0.21
  17. Julien Dilly · 1 shared paper, 2026 · strength 0.21
  18. Kirsten L. Bryant · 1 shared paper, 2026 · strength 0.21
  19. Adrienne D. Cox · 1 shared paper, 2026 · strength 0.21
  20. Sarah E. Ackermann · 1 shared paper, 2026 · strength 0.21
  21. Andrew J. Aguirre · 1 shared paper, 2026 · strength 0.21
  22. Clint A. Stalnecker · 1 shared paper, 2026 · strength 0.21
  23. Andrew M. Waters · 1 shared paper, 2026 · strength 0.21
  24. Channing J. Der · 1 shared paper, 2026 · strength 0.21
  25. G. Aaron Hobbs · 1 shared paper, 2026 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.